接受基于VEGF的治疗性疫苗长期免疫的癌症患者特异性体液和细胞免疫应答
CIGB-247是一种以重组修饰人血管内皮生长因子(VEGF)为抗原、联合细菌来源佐剂VSSP的癌症治疗性疫苗。Ⅰ期临床试验中晚期实体瘤患者接受三个抗原剂量水平的安全性、耐受性和免疫原性研究,存活者自愿接受试验外再免疫。本文对这些人约三年免疫后无额外肿瘤治疗的情况下进行免疫学随访,发现长期接种可行且安全,多数患者维持血清阳转状态,抗VEGF IgG滴度下降但仍高于接种前水平,持续接种促使抗VEGF IgG应答从IgG1向IgG4逐渐偏移,长期试验外接种可能维持能够干扰VEGF/受体相互作用的抗体储备以及CD8+细胞产生IFNγ分泌。作者认为长期治疗性接种是可行策略,并强调继续该候选疫苗临床开发项目的重要性。
要点
- CIGB-247以重组修饰人VEGF为抗原联合VSSP佐剂,在晚期实体瘤患者中三个抗原剂量水平完成Ⅰ期试验。
- 存活者试验外自愿再免疫约三年后,长期接种可行且安全,多数患者维持血清阳转状态。
- 抗VEGF IgG滴度下降但所有病例仍高于接种前水平,持续接种促使抗VEGF IgG应答从IgG1向IgG4逐渐偏移。
核心结论
- 长期治疗性接种是可行策略,并强调继续该新型癌症治疗性疫苗候选物临床开发项目的重要性。
- 长期试验外接种可能与维持能够干扰VEGF/受体相互作用的抗体储备以及CD8+细胞产生IFNγ分泌相关。
研究设计与样本
- CIGB-247是以重组修饰人VEGF为抗原联合细菌来源佐剂VSSP的癌症治疗性疫苗。
- Ⅰ期临床试验在晚期实体瘤患者中研究三个抗原剂量水平的安全性、耐受性和免疫原性。
- 试验存活者自愿接受试验外再免疫,本文对这些人约三年免疫后无额外肿瘤治疗的情况下进行免疫学随访。
主要发现
- 长期接种可行且安全。
- 持续接种后多数患者维持血清阳转状态。
- 特异性抗VEGF IgG滴度下降,但所有病例仍高于接种前水平。
- 持续接种促使抗VEGF IgG应答从IgG1向IgG4逐渐偏移。
- 长期试验外接种可能与维持能够干扰VEGF/受体相互作用的抗体储备以及CD8+细胞产生IFNγ分泌相关。
临床怎么用
- 作者认为长期治疗性接种是可行策略,并强调继续该候选疫苗临床开发项目的重要性。
- 作者强调CIGB-247在癌症中的未来临床应用,并说明未来研究可能解决的知识空白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, tolerance, and immunogenicity of CIGB-247 was studied in patients with advanced solid tumors at three antigen dose level. Surviving individuals of this clinical trial were eligible to receive off-trial voluntary re-immunizations. The present work is focus in the immunological follow up of these patients after approximately three years of immunizations, without additional oncological treatments. Long term vaccination was feasible and safe. Our results indicated that after sustained vaccination most of the patients conserved their seroconversion status. The specific anti-VEGF IgG titer diminished, but in all the cases keeps values up from the pre-vaccination levels. Continued vaccination was also important to produce a gradual shift in the anti-VEGF IgG response from IgG1 to Ig4. Outstanding, our results indicated that long-term off-trial vaccination could be associated with the maintaining of one reserve of antibodies able to interfere with the VEGF/Receptor interaction and the production of IFNγ secretion in CD8+ cells. The results derived from the study of this series of patients suggest that long term therapeutic vaccination is a feasible strategy, and highlight the importance of continuing the clinical development program of this novel cancer therapeutic vaccine candidate. We also highlight the future clinical applications of CIGB-247 in cancer and explain knowledge gaps that future studies may address. Registration number and name of trial registry: RPCEC00000102. Cuban Public Clinical Trial Registry (WHO accepted Primary Registry). Available from: http://registroclinico.sld.cu/.
引用
- Morera Y, Sánchez J, Bequet-Romero M, et al. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine. 2017. PMID: 28536029. doi:10.1016/j.vaccine.2017.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。